Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.37 |
| ▸ | CFTR | P13569 | 6/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | GOT1 | P17174 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12161697 | 0.91 | MAOB (0.46) | P2RY12MAOBFBP1STING1PTGER3 | |
| SCHEMBL13182872 | 0.90 | STING1 (0.42) | MAOBSTING1CFTRLMNAMAPT | |
| SCHEMBL9922655 | 0.90 | P2RY12 (0.47) | P2RY12MAOBFBP1STING1PTGER3 | |
| SCHEMBL14113780 | 0.87 | MEN1 (0.46) | P2RY12FBP1LMNAMAPTMEN1 | |
| SCHEMBL9922954 | 0.86 | P2RY12 (0.44) | P2RY12MAOBFBP1STING1PTGER3 | |
| SCHEMBL12177423 | 0.82 | STING1 (0.46) | P2RY12MAOBSTING1CFTRLMNA | |
| SCHEMBL9922557 | 0.82 | FBP1 (0.45) | P2RY12MAOBFBP1STING1PTGER3 | |
| SCHEMBL9922654 | 0.80 | P2RY12 (0.44) | P2RY12MAOBFBP1STING1LMNA | |
| SCHEMBL13633804 | 0.80 | P2RY12 (0.43) | P2RY12FBP1STING1LMNAMAPT | |
| SCHEMBL9922563 | 0.79 | P2RY12 (0.49) | P2RY12FBP1STING1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | P2RY12 89/4885MAOB 3086/4885FBP1 3837/4885 |
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | P2RY12 18/4885MAOB 3495/4885FBP1 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.